Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

BACKGROUND: The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna, Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to assess the safety and immunogenicity of primary vaccination with VLA2001 versus the ChAdOx1-S (Oxford-AstraZeneca) adenoviral-vectored vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazarus, Rajeka, Querton, Benedicte, Corbic Ramljak, Irena, Dewasthaly, Shailesh, Jaramillo, Juan Carlos, Dubischar, Katrin, Krammer, Michael, Weisova, Petronela, Hochreiter, Romana, Eder-Lingelbach, Susanne, Taucher, Christian, Finn, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444237/
https://www.ncbi.nlm.nih.gov/pubmed/36075233
http://dx.doi.org/10.1016/S1473-3099(22)00502-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444237/
https://www.ncbi.nlm.nih.gov/pubmed/36075233
http://dx.doi.org/10.1016/S1473-3099(22)00502-3

Ejemplares similares